Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the budgetary squeeze from fast-rising costs. In Pennsylvania alone, Medicaid coverage of the drugs is projected to cost $1.3 billion. That’s up from practically nothing several years ago. Pennsylvania and Connecticut are looking to tighten guidelines for people who want to use GLP-1s solely for weight loss. But there remains interest in covering the drugs. An Associated Press analysis using the bill-tracking software Plural shows at least a half-dozen states have bills this year proposing Medicaid coverage.… Continue Reading